Objectives: This study compared 29 drugs for risk of psychiatric hospitalization in bipolar disorders, addressing the evidence gap on the >50 drugs used by US patients for treatment. ), and ziprasidone (RR = 1.25; P = 6.20 × 10 −3 ).
using the OHDSI ETL-CDM Builder tool (https://github.com/OHDSI/ ETL-CDMBuilder). Data were retrieved using custom PostgreSQL queries, and analyzed for 190 894 adults (age 18-64 years) in both outpatient (n = 171 434) and inpatient (n = 19 460) settings who had two or more ICD-9-CM/ICD-10-CM diagnostic codes for BD (296.
[0-1]*, 296. [4] [5] [6] [7] [8] Information Table S1 ). Each drug of interest had at least 250 observations that met study design criteria. Patients diagnosed with schizophrenia, chronic delusional disorders, intellectual disabilities, autism-spectrum disorders, organic mental disorders, and
Parkinson's disease prior to or on the date of treatment start were excluded from the sample, as well as those given anti-dementia drugs (cholinesterase inhibitors and memantine) (Supporting Information Table S2 ). The onset of excluded conditions/drugs after treatment initiation was considered as a censoring event in the competing risks regression.
The following sequence of events ( Figure 1 ) was a necessary condition to include a patient in the analysis: (i) a 12-month "washout" period with no drugs of interest and no hospitalization/emergency room (ER) visit with primary psychiatric code; (ii) an outpatient (cohort A) or inpatient (cohort B) mood episode meta-visit ("index visit") defined as a consecutive sequence of visits, at least one of which had a primary psychiatric diagnosis and non-remission code for BD, SCAD or major depressive disorder (MDD); (iii) the filled prescription of the drug of interest ("index fill") defined as the prescription filled on or before the 4th day after visit/discharge; and (iv) a competing risk event: hospitalization/ER meta-visit with psychiatric code, hospitalization/ER meta-visit without psychiatric code, ending monotherapy (adding/switching to a new drug of interest or stopping therapy), or right censoring. Stopping therapy of interest was defined as a ≥ 30-day gap between the expected date of drug supply ending and subsequent refill. Right censoring events included death, end of data, or onset of excluded conditions. Note that the index meta-visit allowed an MDD code alone, given the fact that all patients in our sample were diagnosed with BD/SCAD at least twice during the observation period, before or after the index visit, and thus were classified as having a bipolar spectrum disorder. If more than one event sequence satisfied the above conditions during the period 2003-2015, only the first one was analysed as part of the study.
Competing risks regression 9 survival analysis with lithium as a reference was used to compare 29 monotherapies with respect to the risk of the first event of interest after the index fill: psychiatric hospitalization/ER visit, non-psychiatric hospitalization/ER visit, or ending monotherapy. The last two events preclude the risk of psychiatric hospitalization/ER visit: medication side effects can trigger a medical emergency or non-adherence. Lumping any of these events with censoring could result in risk overestimation for the outcome of interest. 10 A similar competing risks design was used in a recent study assessing hypothyroidism risk on bipolar disorder medications.
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The following covariates were initially included in the analysis:
patient age, sex, inpatient/outpatient meta-visit, number of patient visit days to any health care provider 1 year prior to the index visit, length of index visit, index episode characteristics (BD/SCAD/ MDD diagnosis, BD subtype, polarity, severity, and psychotic features), procedures related to mental health and injuries as well as procedures potentially influencing the central nervous system (general anesthesia, brain surgeries, and apnea-related procedures), and 55 mental and somatic comorbidities (Tables S3-5 ). The analysis also included 35 classes of medications other than drugs of interest for which the prescription was filled 1 year before and/or on the index fill date. These medications comprised a diverse range of pharmacological groups and medical indications that could contribute to indication bias. A forward stepwise selection procedure was performed to determine the final model covariates, applying a Bonferroni-corrected P-value threshold of 5 × 10 −4 for inclusion, to account for multiple testing with 100 potential covariates.
Covariates with significant mutual correlation were united before being added into the regression model, in particular: (i) "depressive mood episode" included diagnosis of MDD or a BD episode with depressive polarity; (ii) "other drugs acting on central nervous system" included analgesics, non-mood-stabilizing anticonvulsants, anxiolytics, and sedatives. The analgesics group included amitriptyline due to its common use for neuropathic pain management, despite it being classified as a tricyclic AD. Topiramate was classified as a non-mood-stabilizing anticonvulsant and pregabalin and gabapentin were classified as anti-anxiety agents.
To account for possible indication biases, the same regression covariates were used to run psychiatric hospitalization models on sample subsets: patients with and without index depressive mood episode, index manic episode, index psychotic features (including SCAD and acute psychoses), and comorbid drug abuse/dependence, and with inpatient versus outpatient meta-visit. Regression analysis with drugs of interest united into classes was also conducted to explore inter-class variability of outcomes using the same covariates as the main model. This analysis was reproduced in subgroups of patients with index depressive and non-depressive mood episode.
One benefit of our design over an intent-to-treat approach is that it allows modeling of a continuous drug exposure, requiring prescription refills, which is important given adherence issues and high rates of psychiatric drug switching.
The following software was used in the study: PostgresQL ver- ( Table S1 ).
| RE SULTS
One of the pre-specified competing risk events occurred in 50.0% of patients by day 32, in 73.2% of patients by the third month, in 95.1% of patients by year 1, and in 99.9% of patients by year 4.
Therefore, results are reported up to 4 years from the start of monotherapy due to the paucity of longer term observations.
Ending monotherapy was the most common competing risk event by the end of the observation period, whereas psychiatric and non-psychiatric hospitalizations occurred in only 6.4% and 4.8% of cases, respectively (Table S6 ). The majority of patients (53.7%) ended monotherapy within 2 months (30.5% failed to make a refill and 23.1% added/changed to a new drug), and more than two-thirds of patients (67.8%) "dropped out" of monotherapy within 4 months. were associated with significantly higher risk of hospitalization than lithium; the norepinephrine-dopamine reuptake inhibitor bupropion showed a significantly lower risk.
Out of 100 non-treatment covariates tested, 13 were significantly associated with the risk of psychiatric hospitalization in the model: eight of them had elevated risk (inpatient meta-visit, baseline depression and psychosis, comorbid drug abuse/dependence, pulmonary and cardiovascular disorders, loop diuretics, and other drugs acting on the central nervous system) and five had reduced risk (age, antibacterial and non-steroid anti-inflammatory agents, and BD subtypes I and II) ( Table 1 ).
Significant risk differences between drug categories were found for a regression model with the same covariates, but with drugs united into classes (Table S7) Regression analysis in sample subgroups with and without index depressive episode showed that drug associations significant in the main model kept the same direction in both subgroups, except for three ADs (sertraline, fluoxetine and citalopram) non-significantly associated with lower hospitalization risk in non-depressed patients ( Table 2 ). Many of the P-values related to other drugs were not significant in the subgroups either.
The direction of drug associations significant in the main model stayed the same in subgroups of patients with and without comorbid substance use disorder (Tables S8 and S9) , and also among patients in cohorts A (outpatient treatment) and B (inpatient treatment) (Supporting Information Tables S13 and 14) . Again, many of these associations were non-significant. For groups of patients with either an index manic or psychotic episode, sample sizes were too small to derive definitive conclusions about the direction of the factors' associations (Tables S10-S12 ). Non-drug factors identified in the primary regression model mainly retained their direction of association in all studied subgroups.
The regression models with drugs united into classes showed that ADs were associated with higher risk of hospitalization in patients with depressive index mood episode, whereas no significant association was observed for ADs in the non-depressed cohort. The risk of psychiatric hospitalization was not significantly different from lithium for SGAs in both depressed and non-depressed subgroups (Supporting Information Tables S15, S16 ).
| D ISCUSS I ON
Despite an extensive observation period covering the years 2003-2015, the data on drug-dependent hospitalization risk could only be assessed short term, as few patients stayed on a monotherapy for >4 months. Moreover, the data show that one-third of patients failed to make a refill within 60 days after the end of supply. This finding reflects a disturbing trend in mental health care of poor medication adherence among the BD population and unsatisfactory response to first-line monotherapy. Additional qualitative studies are required to shed light on the reasons behind drug switching/ending, whether it is due to clinicians' views on polypharmacy, low patient acceptability or tolerability of the drugs, lack of the actual therapeutic effect of the medication, or other factors.
Given the high rates of patient "dropout" from monotherapy, the associations revealed between drug prescription fill and the risk of psychiatric hospitalization can be biased by enrichment from acutephase treatment. Thus, caution should be used in extrapolating these The model includes 29 drugs with lithium (n = 9702) as a reference, as well as age, sex and other variables that were significant during the stepwise selection procedure. Statistically significant factors are shown in bold.
TA B L E 1 (Continued) .086
Other drugs acting on central nervous system Both models include 29 drugs with lithium (n = 3031 and 6671, respectively) as a reference, as well as age, sex and other variables that were significant during the stepwise selection procedure. Statistically significant factors are shown in bold.
RR, relative risk; CI, confidence interval.
TA B L E 2 (Continued)
| 769
The possibility of indication biases should be recognized when interpreting the data. First, antipsychotics could be prescribed to more severely ill patients, presenting with psychosis, a complex/ atypical symptom profile or a previous history of drug resistance, potentially reflecting predisposition to a more deleterious BD course. For example, clozapine is often prescribed to patients who were non-responders to other therapies. 15 However, the finding that the SGA aripiprazole performed favorably counters the argument that the evidence for the poorly performing antipsychotics is predominantly an artifact of confounding by indication.
Second, as both the baseline depression and AD monotherapy were associated with higher risk of psychiatric hospitalization, it could be inferred that the symptoms rather than the medication The literature on bupropion suggests that it has equivalent effectiveness to other ADs in treatment of depressive states, [23] [24] [25] with contradictory data on manic switch risk. [25] [26] [27] Our findings on the reduced risk of hospitalization associated with bupropion were unexpected, since psychostimulants are known to significantly increase the probability of psychiatric hospitalization due to psychoses and mania. 28 The observation of bupropion's lower risk might be dose-dependent or relevant to certain subgroups of patients in their early course of BD/ SCAD. In a subgroup analysis of patients with substance use disorder, the direction of bupropion's risk remained the same, but was not statistically significant, due to the small sample size (Table S8) . Also, bupropion was associated with reduced hospitalization risk compared to lithium in patients without a depressive index episode, which negates the hypothesis that its observed role is explained only by alleviating depression through psychostimulation ( Table 2) .
Analysis of factors other than drugs of interest showed that the inpatient meta-visit had an RR of 1.68 over the outpatient metavisit for psychiatric hospitalization (P < 2.23 × 10 −308 ), supporting the evidence that previous hospitalization is a strong predictor of subsequent hospital admission in patients with BD. [29] [30] [31] [32] [33] Consistent with our data, baseline substance use disorder, psychosis, and use of anticonvulsants and anxiolytics were previously reported to be risk factors for hospitalization in BD. 30 The findings on the reduced risk of psychiatric hospitalizations for patients on antibiotics and non-steroidal anti-inflammatory drugs contribute to the evidence suggesting the importance of immune alterations, inflammation, and the microbiome in BDs. 34 It is important to consider some additional limitations of the study, Some additional findings from our study need to be emphasized and further explored. Our study indicates that a substantial proportion of BD patients (44.7%) were initially misdiagnosed with MDD.
This finding can explain why AD monotherapy was the most commonly used treatment regimen and is of particular interest given the concerns about AD-induced risk of manic switch, 35 
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